GLPwatch
Papers (12034)
Page 33 of 201, ranked by citation count.
- Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient.
- Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
- Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
- Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.
- Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.
- Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast.
- The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.
- Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
- Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.
- Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.
- Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
- Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis.
- Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart.
- An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke.
- Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways.
- Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
- Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.
- DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce <i>α</i>-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.
- Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
- Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
- Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes.
- Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.
- Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet.
- Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.
- Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
- Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.
- Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.
- Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.
- Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial.
- Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.
- A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.
- Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.
- Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
- Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety.
- A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
- Proteasome dysfunction mediates high glucose-induced apoptosis in rodent beta cells and human islets.
- Acute Kidney Injury Associated With Semaglutide.
- Tirzepatide: A Review in Type 2 Diabetes.
- Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.
- Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
- Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats.
- Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
- Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis.
- Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
- Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
- PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice.
- Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.
- Neuroprotective exendin-4 enhances hypothermia therapy in a model of hypoxic-ischaemic encephalopathy.
- Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease.
- Semaglutide and blood pressure: an individual patient data meta-analysis.
- The effect of fatty diacid acylation of human PYY<sub>3-36</sub> on Y<sub>2</sub> receptor potency and half-life in minipigs.
- As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging.
- Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US.
- GLP-1 analogue liraglutide attenuates CIH-induced cognitive deficits by inhibiting oxidative stress, neuroinflammation, and apoptosis via the Nrf2/HO-1 and MAPK/NF-κB signaling pathways.
- Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
- Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices.
- Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway.
- Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.